Lotte Bjerre Knudsen is a Danish national, born in 1964 in a small town near Copenhagen. She holds a degree in biotechnology from the Technical University of Denmark, and a Doctoral degree in Scientific Medicine from the University of Copenhagen, Denmark. Lotte has been with Novo Nordisk since her university graduation in 1989 and has since then held several positions within the company and is today Chief Scientific Advisor in Research & Early Development. She has deep experience across the entire value chain of drug discovery and development and has published extensively. Lotte is an inventor on many patents, all fully owned by Novo Nordisk. Specifically, to the area of GLP-1, Lotte is a co-inventor of liraglutide and has led all biology research programs for liraglutide and semaglutide from diabetes to obesity, cardiovascular, kidney and Alzheimer’s Disease. She has been part of representing Novo Nordisk in five FDA Advisory committees. Lotte has received numerous awards. Most recently, she was the recipient of the Danish Biotech Life-Time Achievement Award, the Paul Langerhans Award from the German Diabetes Association, and the STAT Biomedical Innovation Award, and a co-recipient of the American Association for the Advancement of Science Mani Bhaumik Breakthrough of the Year Award.